Guardant Health (NASDAQ:GH - Get Free Report) had its target price boosted by equities research analysts at Piper Sandler from $34.00 to $50.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Piper Sandler's price objective points to a potential upside of 15.81% from the company's current price.
Several other analysts also recently issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research note on Monday. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Sanford C. Bernstein reduced their price objective on Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a research report on Wednesday, October 30th. Barclays began coverage on Guardant Health in a research note on Thursday, January 23rd. They set an "overweight" rating and a $60.00 price target for the company. Finally, Raymond James reissued an "outperform" rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Nineteen research analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health currently has a consensus rating of "Buy" and a consensus price target of $48.21.
View Our Latest Analysis on Guardant Health
Guardant Health stock traded up $2.82 during mid-day trading on Wednesday, hitting $43.17. 1,265,016 shares of the company were exchanged, compared to its average volume of 2,524,168. Guardant Health has a 12-month low of $15.81 and a 12-month high of $50.89. The business's 50 day simple moving average is $40.43 and its two-hundred day simple moving average is $31.74. The company has a market capitalization of $5.33 billion, a P/E ratio of -12.14 and a beta of 1.32.
Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Equities research analysts predict that Guardant Health will post -2.9 earnings per share for the current year.
In related news, Director Musa Tariq sold 2,320 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 2,768 shares of company stock valued at $98,798 in the last three months. Corporate insiders own 5.50% of the company's stock.
A number of institutional investors have recently modified their holdings of GH. JNBA Financial Advisors bought a new stake in shares of Guardant Health during the 3rd quarter valued at approximately $26,000. R Squared Ltd acquired a new position in shares of Guardant Health during the fourth quarter worth $26,000. Ashton Thomas Securities LLC bought a new stake in Guardant Health during the 3rd quarter worth $34,000. SBI Securities Co. Ltd. acquired a new position in shares of Guardant Health in the fourth quarter valued at approximately $43,000. Finally, Kimelman & Baird LLC acquired a new stake in Guardant Health in the fourth quarter valued at $58,000. Institutional investors own 92.60% of the company's stock.
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.